What's Going On With Kyntra Bio Stock Tuesday?
Benzinga·2026-02-24 13:27
Kyntra Bio Inc. (NASDAQ:KYNB) , formerly Fibrogen, shares fluctuated in Tuesday’s premarket session as the company announced data from a Phase 1b/2 study of FG-3246 in combination with enzalutamide for treating metastatic castration-resistant prostate cancer.Prostate Cancer Data Shows Response Rate Of 21%The data presented showed a median radiographic progression-free survival (rPFS) of 10.1 months in patients who had progressed on only one prior androgen receptor pathway inhibitor (ARPI).The study included ...